Suggested remit: To appraise the clinical and cost effectiveness of empagliflozin within its marketing authorisation for treating chronic kidney disease.
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Further information DHSC referral received
Process STA Standard
ID number 6131

Provisional Schedule

Expected publication 20 December 2023

Project Team

Project lead Kate Moore

Email enquiries


Companies sponsors Boehringer Ingelheim (empagliflozin)
Others Department of Health and Social Care
  NHS England
Patient carer groups Diabetes UK
  Kidney Care UK
  Kidney Research UK
Professional groups Royal College of Physicians
  Society for DGH Nephrologists
  UK Kidney Association
  UK Renal Pharmacy Group
Comparator companies AstraZeneca (dapagliflozin)
  Eisai Limited
General commentators All Wales Therapeutic and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee


Key events during the development of the guidance:

Date Update
17 November 0003 - 01 December 2023 Final draft guidance
25 April 2023 Invitation to participate
02 November 2022 - 30 November 2022 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
13 October 2022 In progress

For further information on our processes and methods, please see our CHTE processes and methods manual